医学
肺
重症监护医学
梅德林
虚弱指数
老年学
急诊医学
内科学
老年人
风险评估
患者数据
系统回顾
虚弱综合征
儿科
流行病学
物理疗法
作者
Lifeng Liu,Fangyuan Zhang,Xiaonan Sun,Jia Cui,Jianlian Li,Jingxia Sun
标识
DOI:10.21037/jtd-2025-1747
摘要
Background: Older lung cancer patients with frailty are of higher risk of therapeutic side effects and mortality. Despite the fact that the estimated prevalence of frailty among older patients with lung cancer is widely reported, these results have not been synthesized. The aim of this review was to systematically assess the prevalence and related factors of frailty in older patients with lung cancer. Methods: We searched PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang databases for observational studies (published up to January 1, 2025) on the prevalence of frailty in older patients with lung cancer. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included cohort or case-control studies, the Agency for Healthcare Research and Quality (AHRQ) tool was applied to assess the risk of bias in cross-sectional studies. Pooled estimates, subgroup analyses, meta-regression, and publication bias were conducted using Stata 17.0. Results: =99.6%]. Moreover, Egger's regression test suggested no publication bias (P=0.72). Subgroup analyses showed that frailty was more prevalent among female patients, and those older patients ≥70 years old, from developed countries, before radiotherapy, and assessed using the G8 tool. Conclusions: Frailty is prevalent among older patients with lung cancer, and factors such as age, gender, country, treatment status, and frailty tool were associated with frailty. However, the findings should be interpreted with caution due to high heterogeneity and limited data from regions and subgroups. Early and routine frailty assessment with appropriate management may improve prognosis in this population.
科研通智能强力驱动
Strongly Powered by AbleSci AI